ARTICLE | Emerging Company Profile
Crystalys: Aiming for resolution of gout tophi
With an in-licensed asset and $205M, San Diego biotech is hoping to fill a gap in second-line gout therapies in the U.S.
October 3, 2025 1:24 AM UTC
While approved gout treatments reduce serum levels of uric acid, Crystalys believes its in-licensed molecule can resolve uric acid deposits seen in the more advanced form of the condition common in the U.S. It also thinks the therapy’s specificity can help it avoid the pitfalls that derailed another well-known gout therapy a decade ago.
Crystalys Therapeutics Inc. emerged from stealth this week with a $205 million series A financing co-led by Novo Holdings, SR One and Catalys Pacific and a Phase III-ready URAT1 inhibitor, dotinurad, that is approved for gout in China, Japan, the Philippines and Thailand...